Skip to main content
Utility of Human-Derived Models for Glioblastoma.
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
Tissue-Specific Oncogenic Activity of KRASA146T.
Genome-Informed Targeted Therapy for Osteosarcoma.
The genetics of splicing in neuroblastoma.
Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
FGFR fusions in the driver's seat.
G34, another connection between MYCN and a pediatric tumor.
Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer.
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.